36.40
0.91 (2.56%)
| Previous Close | 35.49 |
| Open | 36.85 |
| Volume | 581,960 |
| Avg. Volume (3M) | 1,137,295 |
| Market Cap | 4,018,086,912 |
| Price / Sales | 8.84 |
| Price / Book | 4.96 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 |
| Profit Margin | -60.26% |
| Operating Margin (TTM) | -52.88% |
| Diluted EPS (TTM) | -2.50 |
| Quarterly Revenue Growth (YOY) | 22.20% |
| Total Debt/Equity (MRQ) | 23.72% |
| Current Ratio (MRQ) | 3.26 |
| Operating Cash Flow (TTM) | -186.46 M |
| Levered Free Cash Flow (TTM) | -184.48 M |
| Return on Assets (TTM) | -15.50% |
| Return on Equity (TTM) | -32.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Zai Lab Limited | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | -5.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.60 |
|
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 1.47% |
| % Held by Institutions | 52.08% |
| 52 Weeks Range | ||
| Median | 75.00 (106.04%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 30 Jun 2025 | 75.00 (106.04%) | Buy | 34.97 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHEN YAJING | - | 36.19 | -2,675 | -96,808 |
| DU YING | - | 35.55 | -37,659 | -1,349,489 |
| EDMONDSON FRAZOR TITUS III | - | 36.19 | -5,877 | -212,689 |
| Aggregate Net Quantity | -46,211 | |||
| Aggregate Net Value ($) | -1,658,986 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 35.81 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DU YING | Officer | 02 Jul 2025 | Sell (-) | 7,072 | 35.49 | 250,985 |
| DU YING | Officer | 01 Jul 2025 | Option execute | 18,000 | - | - |
| DU YING | Officer | 30 Jun 2025 | Sell (-) | 6,918 | 34.97 | 241,922 |
| DU YING | Officer | 27 Jun 2025 | Option execute | 17,970 | - | - |
| CHEN YAJING | Officer | 26 Jun 2025 | Sell (-) | 2,675 | 36.19 | 96,808 |
| DU YING | Officer | 26 Jun 2025 | Sell (-) | 23,669 | 36.19 | 856,581 |
| EDMONDSON FRAZOR TITUS III | Officer | 26 Jun 2025 | Sell (-) | 5,877 | 36.19 | 212,689 |
| CHEN YAJING | Officer | 25 Jun 2025 | Option execute | 6,250 | - | - |
| DU YING | Officer | 25 Jun 2025 | Option execute | 58,800 | - | - |
| EDMONDSON FRAZOR TITUS III | Officer | 25 Jun 2025 | Option execute | 14,600 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |